Epicore BioNetworks IncTSXV: EBN

Epicore 2006 Third Quarter Results

· Issued by Epicore BioNetworks Inc via CNW
for the period ended 31 March 2006; currency in US Dollars

EASTAMPTON, NJ, May 30 /CNW/ - Epicore BioNetworks Inc. reports the
results of its third quarter of fiscal 2006 operations. Sales in the quarter
were $743,628, a 47% increase from quarter two, which follows the expected
seasonal pattern. Sales were 7% lower than prior year quarter three ($743,600
versus $798,700). Gross margin decreased from $562,700 to $517,700. Expenses
at $344,900 were 11% above prior year quarter three. The Company recorded a
net income of $164,800 versus net income of $251,400 in prior year quarter
three. Net income per share for the current quarter was $0.007 versus $0.011
in prior year quarter three.
Sales for the quarter reflected the Company's commitment to aquaculture
and its strong position in the Latin American market. Fiscal quarter three
historically is the Company's strongest. The shrimp aquaculture industry is
predominately located in the northern hemisphere so is most active in January
to March as customers prepare for the season. In quarter three 2005 Epicore
had strong sales in most markets. In 2006 Brazil experienced severe disease
problems so bought far less than expected. Distributor realignment in Vietnam
contributed to the shortfall. Strong sales in Latin American pond sector
covered most of the missed sales.
Mexico was our largest sales region with very strong pond product sales.
Using a feed treatment approach Ecuador also had strong pond sales. Epicore's
EPICIN probiotic protected crops from loss to disease and gave large yield
increases compared to untreated ponds. Sales to Asia hatcheries increased 30%
compared to 2005 quarter three. Asian sales were dominated by sales in India,
where Epicore has an excellent distributor and in Thailand, where our algae
growth media is a big success.
Gross margin decreased by $0.05 million due to lower sales volume. The
quality of business as measured by margin percentage was similar to prior year
(70% versus 71%).
Quarterly operating expenses were higher than prior period ($344,800
versus $309,800) due to increased marketing activity, especially in Ecuador
and Asia. Also, a non-recurring research charge was booked in the quarter.
Cost control in non-marketing areas remains an operating priority with a
salary reduction program in place for senior employees.
Cash at the end of March was $0.25 million, a 9% decrease compared to
prior year quarter three. While market conditions remain difficult in several
regions, the Company has positioned itself well to succeed in the important
markets. After a long period of consolidation in very difficult circumstances,
a revitalized management team is looking to move forward more aggressively on
a number of fronts to develop value for shareholders accordingly.

The financial statements of the Company have been prepared in accordance
with US GAAP. Reconciliation with Canadian GAAP may be found in the filed
quarterly financial statements. Epicore BioNetworks Inc. is a public
corporation with a registered office in Calgary, Alberta, Canada and with
shares listed on the TSX Venture Exchange (symbol EBN). (The TSX Venture
Exchange has not reviewed and does not accept responsibility for the adequacy
or accuracy of this release.)


Epicore BioNetworks Inc on 6ix

Story so far

Earlier from Epicore BioNetworks

Later from Epicore BioNetworks

All Epicore BioNetworks news releases